INI-1 整合酶互動者1（鼠單克隆抗體）

廣州健侖生物科技有限公司

INI-1基因是hSWI / SNF染色質(zhì)重塑絡(luò)合物中一個功能未知的蛋白成分的編碼基因，在惡性橫紋肌樣瘤（MRT）中往往會發(fā)生突變或刪除。MRT相對其可它與之疑似疾?。ㄋ枘讣?xì)胞瘤和sPNETs）的整體存活率是相當(dāng)?shù)偷模?MRT的特征是缺乏INI – 1的核標(biāo)記。而大多數(shù)髓母細(xì)胞瘤和sPNETs是以INI – 1作參考的，因而可用于對該類疾病的研究。

我司還提供其它進口或國產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢

INI-1 整合酶互動者1（鼠單克隆抗體）

【產(chǎn)品介紹】

細(xì)胞定位：細(xì)胞核

克隆號：MRQ-27

同型：IgG2a

適用組織：石蠟/冰凍

陽性對照：原始神經(jīng)外胚腫瘤

抗原修復(fù)：熱修復(fù)（EDTA）

抗體孵育時間：30-60min

INI-1

想了解更多的產(chǎn)品及服務(wù)請掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場部】     歐

【】 
【騰訊  】 
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-103室

在過去的幾年里，來自美國洛杉磯兒童醫(yī)院的Tracy Grikscheit一直在研究如何生長出部分小腸。如果成功，這將為腸道衰竭的治療提供一種新的方式。在被新生兒重癥監(jiān)護室收治的患者中，有2%的嬰兒會受到腸道衰竭的影響。該病癥患者5年內(nèi)約有三分之一因此死亡。
Grikscheit團隊的工作為上述研究目標(biāo)的實現(xiàn)提供了迄今zui有前途的跡象。在將裝有人類腸道組織的支架植入小鼠體內(nèi)4周后，Grikscheit和同事發(fā)現(xiàn)，移植組織生長出人類小腸具有的很多特征。它們包括充滿黏液的杯狀細(xì)胞以及釋放腸胃激素的專門細(xì)胞。更重要的是，移植組織表現(xiàn)得像實際腸道一樣：它們能將復(fù)合糖分解成簡單的葡萄糖。相關(guān)成果發(fā)表在《美國生理學(xué)雜志》上。
Grikscheit表示，在小鼠身上開展的研究成為zui終治療嬰兒患者的關(guān)鍵一步。“我們將不得不獲取全部支撐數(shù)據(jù)。不過，坦率地說，我們已經(jīng)開展了盡可能多的研究。”
下一步則將生長出工程化組織的更大樣本。“每次你將事情的規(guī)模擴大，比如從小鼠擴展至人類嬰兒大小，會需要考慮很多不同的情況。目前，我們正致力于此事。”Grikscheit說。
zui近，美國UT西南醫(yī)學(xué)中心的細(xì)胞生物學(xué)家，用一種稱為6-thiodG的小分子靶定染色體端粒，這種小分子能利用細(xì)胞的“生物鐘“來殺死癌細(xì)胞，并減少腫瘤生長。

The INI-1 gene encodes a protein of unknown function in hSWI / SNF chromatin remodeling complexes, often mutated or deleted in malignant rhabdomyosarcomas (MRT). The overall survival of MRT versus its suspected and suspected diseases (medulloblastoma and sPNETs) is rather low, and MRT is characterized by a lack of INI - 1 nuclear markers. However, most medulloblastomas and sPNETs are based on INI - 1 and are therefore useful for the study of these diseases.

Tracy Grikscheit from Los Angeles Children's Hospital in the United States has been studying how to grow part of the small intestine in the past few years. If successful, this will provide a new way of treating gut failure. In patients admitted to the neonatal intensive care unit, 2% of infants are affected by intestinal failure. About one-third of patients with the condition die within five years.
The latest work done by the Grikscheit team provides the most promising indications so far for the achievement of these research goals. After 4 weeks of implanting a human gut-mounted scaffold into mice, Grikscheit and colleagues found that the transplanted tissue grew many of the features that the human small intestine has. They include mucus-filled goblet cells and specialized cells that release gastrointestinal hormones. More importantly, the transplanted tissues behave like the real intestine: they break down complex sugars into simple glucose. Relevant results published in the "American Journal of Physiology".
Grikscheit said research conducted in mice is a crucial step toward ultimay treating infants. "We will have to get all the support data, but frankly, we have done as much research as possible."
The next step will be to grow a larger sample of engineered organizations. "Every time you scale things up, such as scaling from mice to human baby sizes, there are many different things to consider, and we're working on it right now," says Grikscheit.
Recently, cell biologists at the UT Southwestern Medical Center in the United States targeted chromosomal omeres with a small molecule called 6-thiodG that uses the cell's "biological clock" to kill cancer cells and reduce tumors Grow.